Mitochondria and the link between neuroinflammation and neurodegeneration

Journal of Alzheimer's Disease

Volumn 20, Issue SUPPL.2, 2010, Pages

  Di Filippo, Massimiliano ^a,b   Chiasserini, Davide ^a,b   Tozzi, Alessandro ^a,b   Picconi, Barbara ^b   Calabresi, Paolo ^a,b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Inflammation; mitochondria; multiple sclerosis; neurodegeneration; Parkinson's disease

Indexed keywords

DJ 1 PROTEIN; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PARKIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ALZHEIMER DISEASE; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; HELPER CELL; IMMUNE DYSREGULATION; MICROGLIA; MITOCHONDRION; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NITROSATIVE STRESS; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENICITY; PRIORITY JOURNAL; RESPIRATORY CHAIN; REVIEW;

EID: 77956198871     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-100543     Document Type: Review

References (94)

1. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9, 46-56.
2. Hemmer B, Archelos JJ, Hartung HP (2002) New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neu- rosci 3, 291-301.
3. Meisel C, Schwab JM, Prass K, Meisel A, Dirnagl U (2005) Central nervous system injury-induced immune deficiency syndrome. Nat Rev Neurosci 6, 775-786.
4. Volterra A, Meldolesi J (2005) Astrocytes, from brain glue to communication elements: the revolution continues. Nat Rev Neurosci 6, 626-640.
5. Di Filippo M, Sarchielli P, Picconi B, Calabresi P (2008) Neu- roinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders. Trends Pharmacol Sci 29, 402-412.
6. Rivest S (2009) Regulation of innate immune responses in the brain. Nat Rev Immunol 9, 429-439.
7. Cserr HF, Knopf PM (1992) Cervical lymphatics, the blood- brain barrier and the immunoreactivity of the brain: a new view. Immunol Today 13, 507-512.
8. Nguyen MD, Julien JP, Rivest S (2002) Innate immunity: the missing link in neuroprotection and neurodegeneration? Nat Rev Neurosci 3, 216-227.
9. Compston A, Coles A (2008) Multiple sclerosis. Lancet 372, 1502-1517.
10. Heneka MT, O'Banion MK (2007) Inflammatory processes in Alzheimer's disease. J Neuroimmunol 184, 69-91.
11. Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 8,382397.
12. Bjorkqvist M, Wild EJ, Tabrizi SJ (2009) Harnessing immune alterations in neurodegenerative diseases. Neuron 64, 21-24.
13. Aktas O, Ullrich O, Infante-Duarte C, Nitsch R, Zipp F (2007) Neuronal damage in brain inflammation. ArchNeurol 64, 185189.
14. Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, Gudz T, Macklin WB, Lewis DA, Fox RJ, Rudick R, Mirnics K, Trapp BD (2006) Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 59, 478-489.
15. Mahad D, Ziabreva I, Lassmann H, Turnbull D (2008) Mi- tochondrial defects in acute multiple sclerosis lesions. Brain 131, 1722-1735.
16. Mahad DJ, Ziabreva I, Campbell G, Lax N, White K, Hanson PS, Lassmann H, Turnbull DM (2009) Mitochondrial changes within axons in multiple sclerosis. Brain 132, 1161-1174.
17. Abou-Sleiman PM, Muqit MM, Wood NW (2006) Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 7, 207-219.
18. Gubellini P, Picconi B, Di Filippo M, Calabresi P (2010) Downstream mechanisms triggered by mitochondrial dysfunction in the basal ganglia: from experimental models to neu- rodegenerative diseases. Biochim Biophys Acta 1802, 151161.
19. Parker WD, Jr., Boyson SJ, Parks JK (1989) Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26, 719-723.
20. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Mars- den CD (1989) Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1, 1269.
21. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, At- wood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shi- mohama S, Cash AD, Siedlak SL, Harris PL, Jones PK, Pe- tersen RB, Perry G, Smith MA (2001) Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21, 3017-3023.
22. Querfurth HW, LaFerla FM (2010) Alzheimer's disease. N Engl J Med 362, 329-344.
23. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, Bird ED, Beal MF (1997) Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 41, 646-653.
24. Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, Gan WB (2005) ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 8, 752-758.
25. Nimmerjahn A, Kirchhoff F, Helmchen F (2005) Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308, 1314-1318.
26. Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG (2009) Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener 4, 47.
27. Block ML, Zecca L, Hong JS (2007) Microglia-mediated neu- rotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8, 57-69.
28. Babior BM (2004) NADPH oxidase. Curr Opin Immunol 16, 42-47.
29. Poyton RO, Ball KA, Castello PR (2009) Mitochondrial generation offree radicals and hypoxic signaling. Trends Endocrinol Metab 20, 332-340.
30. Balaban RS, Nemoto S, Finkel T (2005) Mitochondria, oxi- dants, and aging. Cell 120, 483-495.
31. Fukui H, Moraes CT (2008) The mitochondrial impairment, oxidative stress and neurodegeneration connection: reality or just an attractive hypothesis? Trends Neurosci 31, 251-256.
32. Calabrese V, Mancuso C, Calvani M, Rizzarelli E, Butterfield DA, Stella AM (2007) Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat Rev Neurosci 8, 766-775.
33. Bal-Price A, Brown GC (2001) Inflammatory neurodegener- ation mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotox- icity. J Neurosci 21, 6480-6491.
34. Stewart VC, Sharpe MA, Clark JB, Heales SJ (2000) Astrocyte-derived nitric oxide causes both reversible and irreversible damage to the neuronal mitochondrial respiratory chain. J Neurochem 75, 694-700.
35. Bazzoni F, Beutler B (1996) The tumor necrosis factor ligand and receptor families. N Engl J Med 334, 1717-1725.
36. Beattie EC, Stellwagen D, Morishita W, Bresnahan JC, Ha BK, Von ZM, Beattie MS, Malenka RC (2002) Control of synaptic strength by glial TNFalpha. Science 295, 2282-2285.
37. Stommel EW, van Hoff RM, Graber DJ, Bercury KK, Lang- ford GM, Harris BT (2007) Tumor necrosis factor-alpha induces changes in mitochondrial cellular distribution in motor neurons. Neuroscience 146, 1013-1019.
38. Ferri A, Nencini M, Cozzolino M, Carrara P, Moreno S, Car- ri MT (2008) Inflammatory cytokines increase mitochondri- al damage in motoneuronal cells expressing mutant SOD1. Neurobiol Dis 32, 454-460.
39. Druzhyna NM, Musiyenko SI, Wilson GL, LeDoux SP (2005) Cytokines induce nitric oxide-mediated mtDNA damage and apoptosis in oligodendrocytes. Protective role of targeting 8- oxoguanine glycosylase to mitochondria. J Biol Chem 280, 21673-21679.
40. Takeuchi H, Jin S, Wang J, Zhang G, Kawanokuchi J, Kuno R, Sonobe Y, Mizuno T, Suzumura A (2006) Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J Biol Chem 281, 21362-21368.
41. Huang Y, Erdmann N, Peng H, Zhao Y, Zheng J (2005) The role of TNF related apoptosis-inducing ligand in neurodegen- erative diseases. Cell Mol Immunol 2, 113-122.
42. Aktas O, Smorodchenko A, Brocke S, Infante-Duarte C, Schulze TU, Vogt J, Prozorovski T, Meier S, Osmanova V, Pohl E, Bechmann I, Nitsch R, Zipp F (2005) Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 46, 421-432.
43. Marzo I, Brenner C, Zamzami N, Jurgensmeier JM, Susin SA, Vieira HL, Prevost MC, Xie Z, Matsuyama S, Reed JC, Kroemer G (1998) Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science 281, 2027-2031.
44. Green DR, Kroemer G (2004) The pathophysiology of mito- chondrial cell death. Science 305, 626-629.
45. Allan SM, Rothwell NJ (2001) Cytokines and acute neurode- generation. Nat Rev Neurosci 2, 734-744.
46. Wallace DC (1999) Mitochondrial diseases in man and mouse. Science 283, 1482-1488.
47. Di Filippo M, Picconi B, Costa C, Bagetta V, Tantucci M, Parnetti L, Calabresi P (2006) Pathways of neurodegeneration and experimental models of basal ganglia disorders: downstream effects of mitochondrial inhibition. Eur J Pharmacol 545, 65-72.
48. Hinchliffe P, Sazanov LA (2005) Organization of iron-sulfur clusters in respiratory complex I. Science 309, 771-774.
49. Perier C, Bove J, Vila M, Przedborski S (2003) The rotenone model of Parkinson's disease. Trends Neurosci 26, 345-346.
50. Costa C, Belcastro V, Tozzi A, Di Filippo M, Tantucci M, Siliquini S, Autuori A, Picconi B, Spillantini MG, Fedele E, Pittaluga A, Raiteri M, Calabresi P (2008) Electrophysiology and pharmacology of striatal neuronal dysfunction induced by mitochondrial complex I inhibition. JNeurosci 28, 8040-8052.
51. Gao HM, Liu B, Hong JS (2003) Critical role for mi- croglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 23, 6181-6187.
52. Sherer TB, Betarbet R, Kim JH, Greenamyre JT (2003) Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci Lett 341, 87-90.
53. Shaikh SB, Nicholson LF (2009) Effects of chronic low dose rotenone treatment on human microglial cells. Mol Neurode- gener 4, 55.
54. Gao HM, Hong JS, Zhang W, Liu B (2003) Synergistic dopaminergic neurotoxicity of the pesticide rotenone and in- flammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. J Neurosci 23, 1228-1236.
55. Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, Fisone G, Cenci MA, Calabresi P (2003) Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6, 501-506.
56. Schwarting RK, Huston JP (1996) Unilateral 6-hydroxydopa- mine lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog Neurobiol 49, 215-266.
57. Long-Smith CM, Sullivan AM, Nolan YM (2009) The influence of microglia on the pathogenesis of Parkinson's disease. Prog Neurobiol 89, 277-287.
58. Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, Duyckaerts C, Flavell RA, Hirsch EC, Hunot S (2009) Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119, 182-192.
59. McGeer PL, McGeer EG (2008) Glial reactions in Parkinson's disease. Mov Disord 23, 474-483.
60. Gao HM, Liu B, Zhang W, Hong JS (2003) Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEBJ17, 1954-1956.
61. Napolitano M, Centonze D, Gubellini P, Rossi S, Spiezia S, Bernardi G, Gulino A, Calabresi P (2004) Inhibition of mi- tochondrial complex II alters striatal expression of genes involved in glutamatergic and dopaminergic signaling: possible implications for Huntington's disease. Neurobiol Dis 15, 407-414.
62. Saulle E, Gubellini P, Picconi B, Centonze D, Tropepi D, Pisani A, Morari M, Marti M, Rossi L, Papa M, Bernardi G, Calabresi P (2004) Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington's disease. Mol Cell Neurosci 25, 9-20.
63. Brouillet E, Conde F, Beal MF, Hantraye P (1999) Replicating Huntington's disease phenotype in experimental animals. Prog Neurobiol 59, 427-468.
64. Picconi B, Passino E, Sgobio C, Bonsi P, Barone I, Ghiglieri V, Pisani A, Bernardi G, Ammassari-Teule M, Calabresi P (2006) Plastic and behavioral abnormalities in experimental Hunt- ington's disease: a crucial role for cholinergic interneurons. Neurobiol Dis 22, 143-152.
65. Ryu JK, Nagai A, Kim J, Lee MC, McLarnon JG, Kim SU (2003) Microglial activation and cell death induced by the mitochondrial toxin 3-nitropropionic acid: in vitro and in vivo studies. Neurobiol Dis 12, 121-132.
66. Beal MF (2005) Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 58, 495-505.
67. Di Filippo M, Anderson VM, Altmann DR, Swanton JK, Plant GT, Thompson AJ, Miller DH (2010) Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 81, 204-208.
68. Martino G, Adorini L, Rieckmann P, Hillert J, Kallmann B, Comi G, Filippi M (2002) Inflammation in multiple sclerosis: the good, the bad, and the complex. Lancet Neurol 1, 499-509.
69. Merrill JE, Benveniste EN (1996) Cytokines in inflammatory brain lesions: helpful and harmful. Trends Neurosci 19, 331338.
70. Imitola J, Chitnis T, Khoury SJ (2006) Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implications for future therapies. Arch Neurol 63, 25-33.
71. Mao P, Reddy PH (2010) Is multiple sclerosis a mitochondrial disease? Biochim Biophys Acta 1802, 66-79.
72. Waxman SG (2006) Axonal conduction and injury in multiple sclerosis: the role of sodium channels. Nat Rev Neurosci 7, 932-941.
73. Trapp BD, Stys PK (2009) Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 8, 280-291.
74. Lees AJ, Hardy J, Revesz T (2009) Parkinson's disease. Lancet 373, 2055-2066.
75. Calabresi P, Picconi B, Parnetti L, Di Filippo M (2006) A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance. Lancet Neurol 5, 974-983.
76. Calabresi P, Picconi B, Tozzi A, Di Filippo M (2007) Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci 30, 211-219.
77. Klein C, Schlossmacher MG (2007) Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder. Neurology 69, 2093-2104.
78. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine- analog synthesis. Science 219, 979-980.
79. Di Filippo M, Tambasco N, Muzi G, Balucani C, Saggese E, Parnetti L, Calabresi P, Rossi A (2008) Parkinsonism and cognitive impairment following chronic exposure to potassium cyanide. Mov Disord 23, 468-470.
80. Dinis-Oliveira RJ, Remiao F, Carmo H, Duarte JA, Navarro AS, Bastos ML, Carvalho F (2006) Paraquat exposure as an etiological factor of Parkinson's disease. Neurotoxicology 27, 1110-1122.
81. Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39, 889-909.
82. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Mars- den CD (1990) Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54, 823-827.
83. Jenner P, Olanow CW (1996) Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47, S161-S170.
84. Levesque S, Wilson B, Gregoria V, Thorpe LB, Dallas S, Po- likov VS, Hong JS, Block ML (2010) Reactive microglio- sis: extracellular {micro}-calpain and microglia-mediated dopaminergic neurotoxicity. Brain 133, 808-821
85. Jenner P, Olanow CW (2006) The pathogenesis of cell death in Parkinson's disease. Neurology 66, S24-S36.
86. Le W, Rowe D, Xie W, Ortiz I, He Y, Appel SH (2001) Mi- croglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J Neurosci 21, 84478455.
87. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, Knapp DJ, Crews FT (2007) Systemic LPS causes chronic neuroin- flammation and progressive neurodegeneration. Glia 55, 453462.
88. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403.
89. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21, 383-421.
90. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140,918-934.
91. Yamamoto M, Kiyota T, Horiba M, Buescher JL, Walsh SM, Gendelman HE, Ikezu T (2007) Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP trans- genic mice. Am J Pathol 170, 680-692.
92. Moreira PI, Carvalho C, Zhu X, Smith MA, Perry G (2010) Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. Biochim Biophys Acta 1802, 2-10.
93. Reddy PH, Beal MF (2008) Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med 14, 45-53.
94. Reddy PH (2009) Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease. Exp Neurol 218, 286-292.